Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Cheplapharm Initiates LLP Acquisitions in Japan, Eyes 10 Asset Takeovers in 2024: Local Head
December 15, 2023
- Taisho Aims to Make “Alli” 5th Leg of Its Consumer Healthcare Biz, Eyes Annual Sales of 2-3 Billion Yen
December 15, 2023
- JCR Bags FDA’s Orphan Tag for MPS IIIA Drug in US
December 15, 2023
- Shionogi Ships 1st Batch of Cough Drug Medicon after Ramp-Up
December 15, 2023
- Leqembi to Debut on Dec. 20; Eisai Sees SC Version and Blood Biomarker as Drivers for Wider Use
December 14, 2023
- Novo Nordisk Expects to Lift Restrictions on Ozempic Shipments in Early January
December 14, 2023
- Torii Scoops Up Japan Rights for Grass Pollinosis Med
December 14, 2023
- Avastin Biosimilars Add Malignant Glioma Indication in Japan
December 14, 2023
- Prograf Generics Now on Equal Footing with Original Product
December 14, 2023
- Mochida Intends to Carve Out Market Share with 1st G-Lasta Biosimilar
December 13, 2023
- GSK Seeks Label Expansion of Arexvy for High-Risk Adults Aged 50-59
December 13, 2023
- Total Sales of 26 Japan Drug Makers Up 6.1% in H1; Shionogi Nets Largest Growth
December 12, 2023
- Sobi Eyes Japan Approval of 4 Rare Disease Drugs in 5 Years: Local Chief
December 12, 2023
- Astellas’ Hot Flash Drug Bags European Nod
December 12, 2023
- Lenvima-Keytruda Combo Misses Goal in 1st Line Endometrial Cancer
December 12, 2023
- NEC Harnessing AI Prowess to Pursue Global Players in Cancer Vaccine Race
December 11, 2023
- KM, Meiji Initiate PIII Pediatric Trial for XBB.1.5-Adapted COVID Vaccine
December 8, 2023
- Pivlaz Approved in South Korea, Set for Launch in Early 2025
December 8, 2023
- Japan Ethical Drug Sales Up 8.4% in October: Crecon
December 8, 2023
- Keytruda Scores No. 1 in Japan Sales Ranking in November: Encise
December 8, 2023
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…